Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study - PubMed
3 hours ago
- #Pembrolizumab
- #Biliary Tract Cancer
- #Hepatitis B
- The KEYNOTE-966 trial showed that pembrolizumab plus chemotherapy improved overall survival (OS) in advanced biliary tract cancer patients.
- This post hoc analysis examined the impact of hepatitis B virus (HBV) infection on the efficacy and safety of pembrolizumab plus chemotherapy.
- Among 1069 participants, 30.8% were HBV-positive (30 chronic, 299 resolved).
- OS hazard ratios were similar for HBV-positive (HR 0.87) and HBV-negative (HR 0.85) subgroups.
- Safety profiles were consistent between HBV-positive and HBV-negative participants.
- HBV reactivation occurred in 8 participants (5 pembrolizumab, 3 placebo), with no HBV-associated hepatitis cases.
- Efficacy and safety outcomes were consistent regardless of HBV status.